Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the US Food and Drug Administration (FDA) for adults with relapsed or refractory ...
Alzheimer’s has long been considered irreversible, but new research challenges that assumption. Scientists discovered that severe drops in the brain’s energy supply help drive the disease—and ...
For more than a century, people have considered Alzheimer's disease (AD) an irreversible illness. Consequently, research has focused on preventing or slowing it, rather than recovery. Despite billions ...
Washington, D.C.: The Executive Board of the International Monetary Fund (IMF) has formally completed its review of the Short-Term Liquidity Line (SLL) on December 15th. The Review concluded that the ...
Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...
At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...
Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...
Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results. Will dialysis and organ transplants become a thing of the past? A healthy ...
Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results